Healthcare -
Biotechnology - NASDAQ - CA
$ 3.48
-5.18 %
$ 12.9 M
Market Cap
-0.26
P/E
1. INTRINSIC VALUE
FINANCIALS
Balance Sheet
BriaCell Therapeutics Corp.
| Current Assets | 3.65 M |
| Cash & Short-Term Investments | 862 K |
| Receivables | 1.37 M |
| Other Current Assets | 1.42 M |
| Non-Current Assets | 2.22 M |
| Long-Term Investments | 418 K |
| PP&E | 388 K |
| Other Non-Current Assets | 1.41 M |
| Current Liabilities | 7.46 M |
| Accounts Payable | 7.17 M |
| Short-Term Debt | 0 |
| Other Current Liabilities | 290 K |
| Non-Current Liabilities | 1.1 M |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 1.1 M |
EFFICIENCY
Earnings Waterfall
BriaCell Therapeutics Corp.
| Revenue | 0 |
| Cost Of Revenue | 82.6 K |
| Gross Profit | -82.6 K |
| Operating Expenses | 32.7 M |
| Operating Income | -32.8 M |
| Other Expenses | -27.9 M |
| Net Income | -4.93 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
BriaCell Therapeutics Corp.
| Net Income | -4.93 M |
| Depreciation & Amortization | 83.9 K |
| Capital Expenditures | -457 K |
| Stock-Based Compensation | 1.8 M |
| Change in Working Capital | 7.05 M |
| Others | -27.1 M |
| Free Cash Flow | -24.6 M |
Wall Street Analysts Price Targets
BriaCell Therapeutics Corp.
BCTX has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
BCTX does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
BriaCell Therapeutics Corp.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
3.91 M USD 1
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
9 months ago
May 14, 2024
|
Bought
2 M USD
|
Lustig Marc
director, 10 percent owner:
|
+ 902935
|
2.215 USD |
|
9 months ago
May 14, 2024
|
Bought
1.91 M USD
|
Lustig Marc
director, 10 percent owner:
|
+ 902935
|
2.11 USD |
|
2 years ago
Dec 28, 2022
|
Bought
128 K USD
|
Bondarenko Jamieson
Chairman
|
+ 28000
|
4.58 USD |
|
2 years ago
Dec 23, 2022
|
Bought
4.91 K USD
|
Williams William V.
President, CEO
|
+ 2530
|
1.94 USD |
|
2 years ago
Dec 20, 2022
|
Bought
118 K USD
|
Bondarenko Jamieson
Director
|
+ 22000
|
5.35 USD |
7. News
Biotechs on the Brink: 2 Stocks With Huge Potential
Investors know the biotech industry is a waiting game—smaller companies in this space often work to secure the funding to keep their doors open during a pre-revenue period while they develop drug treatments and other medical products, but the process can be slow and, for those on the outside, opaque. Then, if all goes according to plan, these firms may see success in the form of promising data, successful trial results, or approval from a regulatory agency like the FDA.
marketbeat.com
- 2 weeks ago
BRIACELL THERAP (BCTX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for BRIACELL THERAP (BCTX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
zacks.com
- 2 weeks ago
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general meeting of shareholders of the Company (the “Shareholders”) for the year ended July 31, 2024 held on February 5, 2025 (the “Meeting”). A total of 36.26% of the Company's issued and outstanding common shares (the “Common Shares”) were voted at the Meeting.
globenewswire.com
- 3 weeks ago
BriaCell Therapeutics Announces Closing of Public Offering
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced best-efforts public offering of 762,500 common shares at a public offering price of $4.00 per share. The Company received gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, of $3.05 million. The Company relied upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq.
globenewswire.com
- 3 weeks ago
BRIACELL THERAP (BCTX) Upgraded to Buy: What Does It Mean for the Stock?
BRIACELL THERAP (BCTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
- 3 weeks ago
BriaCell Therapeutics Announces Pricing of Public Offering
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts public offering of 762,500 common shares at a public offering price of $4.00 per share. Total gross proceeds from the offering, before deducting placement agent fees and other offering expenses, are expected to be $3.05 million. The offering is expected to close on February 5, 2025, subject to satisfaction of customary closing conditions. The Company is relying upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq.
globenewswire.com
- 4 weeks ago
BriaCell Therapeutics Announces Proposed Public Offering of Common Shares
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced that it intends to offer to sell common shares in a best-efforts public offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the size or terms of the offering. The Company is relying upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq.
globenewswire.com
- 4 weeks ago
BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS™
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce an unprecedented clinical response including resolution of a lung metastasis (breast cancer tumor that spread to the lung) with stable disease elsewhere. This patient is the first metastatic breast cancer (MBC) patient treated with Bria-OTS™.
globenewswire.com
- 4 weeks ago
BriaCell Announces Completion of 15:1 Share Consolidation
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 27, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announces that on January 24, 2025 (the “Effective Date”), the Company completed a share consolidation (the “Consolidation”) of the Company's issued and outstanding common shares (the “Common Shares”) on the basis of one (1) post-Consolidation Common Share for every fifteen (15) pre-Consolidation Common Shares. The Consolidation is being implemented to ensure that the Company continues to comply with the listing requirements of The Nasdaq Capital Market (the “Nasdaq”).
globenewswire.com
- 1 month ago
BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company will be relying on, and has satisfied all of the conditions to rely on, CSA Coordinated Blanket Order 51-931 for exemption from the requirements to send proxy-related materials (the "Meeting Materials") for its upcoming annual general meeting (the "Meeting") to be held on Thursday, January 23, 2025, at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. at 10:00 a.m. (EST) due to the suspension of mail service in Canada from the nationwide strike of the Canadian Union of Postal Workers that commenced on November 15, 2024.
globenewswire.com
- 2 months ago
BriaPro Therapeutics Corp. Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures
VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- BriaPro Therapeutics Corp. (“BriaPro” or the “Company”), a pre-clinical stage immunotherapy company developing binding agents and proteins with the intention to boost the ability of the body's own cancer-fighting cells to destroy cancerous tumors, announces that the Company will be relying on, and has satisfied all of the conditions to rely on, CSA Coordinated Blanket Order 51-931 for exemption from the requirements to send proxy-related materials (the “Meeting Materials”) for its upcoming annual general meeting (the “Meeting”) to be held on Thursday, January 23, 2025, at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. at 10:30 a.m. (EST) due to the suspension of mail service in Canada from the nationwide strike of the Canadian Union of Postal Workers that commenced on November 15, 2024. The Meeting Materials have been posted under the Company's profile on SEDAR+ at www.sedarplus.ca (“SEDAR+”) and on the Company's website at https://investors.briacell.com/briapro.
globenewswire.com
- 2 months ago
BriaCell Therapeutics Announces Closing of $5.5 Million Public Offering
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 13, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced underwritten public offering of 7,400,000 common shares and warrants to purchase 7,400,000 common shares at a combined public offering price of $0.75 per share and associated warrant. The warrants have an exercise price of $0.9375 per share and are immediately exercisable upon issuance for a period of five years following the date of issuance. Total gross proceeds from the offering, before deducting the underwriter's discounts and other offering expenses, is $5.55 million.
globenewswire.com
- 2 months ago
8. Profile
Summary
BriaCell Therapeutics Corp. BCTX
COUNTRY
CA
INDUSTRY
Biotechnology
MARKET CAP
$ 12.9 M
Dividend Yield
0.00%
Description
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
Contact
Bellevue Centre, West Vancouver, BC, V7T 2X1
https://www.briacell.com
IPO
Date
March 14, 2012
Employees
16
Officers
Dr. Giuseppe Del Priore M.D., M.P.H., MPH
Chief Medical Officer
Dr. Charles Louis Wiseman FACP, M.D.
Founder, Principal Research Advisor & Member of Scientific Advisory Board
Mr. Gadi Levin B.Com., C.A., CPA, M.B.A.
Chief Financial Officer & Corporate Secretary
Dr. Miguel A. Lopez-Lago Ph.D.
Chief Scientific Officer
Dr. William V. Williams M.D.
Chief Executive Officer, President & Director